Loading stock…

Samsung Biologics Co.,Ltd. (A207940) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Samsung Biologics Co.,Ltd.

A207940Market cap $45BPrice $979.3

Country🇰🇷South Korea

SectorHealthcare

IndustryLife Sciences

Manufactures vaccines and biologics for pharmaceutical giants worldwide, handling complex drugs that traditional factories can't produce. Controls one of Asia's largest biomanufacturing capacities, making medications for millions of patients globally.

In Bastion Portfolios?

52W Return-2%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+10%7

Revenue Forecast

Rev CAGR (1y)+30%9

Rev CAGR (3y)+17%9

Rev CAGR (5y)+15%9

Earnings Forecast

EPS Growth Y+1+16%8

EPS Growth Y+2+17%8

EPS Growth Y+3+18%8

Quality

Margins

EBIT Margin45%10

Net Income Margin39%10

Free Cash Flow Margin32%9

Debt

Net Debt/EBITDA-0.310

Efficiency

ROE19%8

ROA13%9

Earnings Stability1010

GEAR+VERY STRONG96

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)292

P/E Ratio (Forward 3y)232

P/BV7.22

EV Multiples

EV/EBITDA Fwd212

EV/EBIT Fwd243

Yield

Free Cash Flow Yield2.7%4

Dividend Yieldna–

Momentum

Short term

1 month return-9%3

3 month return-6%4

YTD return-21%2

Mid term

Price vs 52wHigh66%3

1 year return+4%5

Long term

3 year return+44%5

5 year return+31%5

Risk Shield

Price Risk

Beta0.48

Volatility45%4

Free Cash Flow

Free Cash Flow Margin32%9

Free Cash Flow Yield2.7%4

Quality

ROCE20%9

Earnings Stability1010

Net Debt/EBITDA-0.310

02Growth

Is it actually growing, and how fast?

A207940Samsung Biologics Co.,Ltd.

Revenue FY25$3.2B

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+30%9

Revenue, next 3Y, CAGR+17%9

Revenue, next 5Y, CAGR+15%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+16%8

EPS growth, FY27E+17%8

EPS growth, FY28E+18%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 17%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 10%/yr over the last 3 years and is set to grow 17%/yr from here.

The runway holds up: revenue is set to grow 15%/yr over five years.9/10

Earnings are set to grow in step with sales (EPS about 17%/yr vs revenue 17%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

A207940Samsung Biologics Co.,Ltd.

Total return Current409%

Price return Current409%

MOMENTUM RATING↗

WEAK26 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-9%3

3-month return-6%4

YTD return-21%2

MID & LONG-TERM▾SCORE

% of 52-week high66%3

1-year return+4%5

3-year return+44%5

5-year return+31%5

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+44% over three years and +31% over five), roughly average for the market.

It's up 4% over the past year, but 34% below its 52-week high. That is a touch behind the market.

Returns sit at the market level over three months (-6%).

WEAKNESSES

The stock is underperforming over the past month (-9%) and so far this year (-21%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the stock is underperforming over the past month and so far this year.

04Value

Are you paying a fair price for it?

Stop guessing on Samsung Biologics. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

A207940Samsung Biologics Co.,Ltd.

Revenue FY25$3.2B

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+30%9

Revenue, next 3Y, CAGR+17%9

Revenue, next 5Y, CAGR+15%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+16%8

EPS growth, FY27E+17%8

EPS growth, FY28E+18%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 17%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 10%/yr over the last 3 years and is set to grow 17%/yr from here.

The runway holds up: revenue is set to grow 15%/yr over five years.9/10

Earnings are set to grow in step with sales (EPS about 17%/yr vs revenue 17%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

A207940Samsung Biologics Co.,Ltd.

Total return Current409%

Price return Current409%

MOMENTUM RATING↗

WEAK26 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-9%3

3-month return-6%4

YTD return-21%2

MID & LONG-TERM▾SCORE

% of 52-week high66%3

1-year return+4%5

3-year return+44%5

5-year return+31%5

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+44% over three years and +31% over five), roughly average for the market.

It's up 4% over the past year, but 34% below its 52-week high. That is a touch behind the market.

Returns sit at the market level over three months (-6%).

WEAKNESSES

The stock is underperforming over the past month (-9%) and so far this year (-21%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Samsung Biologics. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community